# Study for AZD4360 in Participants With Advanced Solid Tumours

Source: https://onco.cc/trials/nct06921928/  
OnCo record `nct06921928` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD4360 in pancreatic ductal adenocarcinoma, run by AstraZeneca, active and no longer recruiting.

## Summary

Study for AZD4360 in Participants With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06921928 by AstraZeneca, with 31 participants enrolled, started 2025-04-29 and due to reach its primary completion in 2027-03-31. Interventions recorded: AZD4360. Conditions listed: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06921928
- Phase: 1/2
- Setting: A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours
- Sponsor: AstraZeneca
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT06921928: https://clinicaltrials.gov/study/NCT06921928

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [AZD4360](https://onco.cc/drugs/azd4360/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06921928.json